ADVVF 股息： Advicenne SA 收益洞察

Q: Advicenne SA 的关键财务报表是什么？

根据最新的财务报表（Form-10K），Advicenne SA 的总资产为 $9，净损失为 $-6

Q: ADVVF 的关键财务比率是什么？

Advicenne SA 的流动比率是 0.32，净利 margin 为 -300，每股销售为 $0.16。

Q: Advicenne SA 的收入按细分市场或地理位置如何划分？

Advicenne SA 最大收入来源是 Pharmaceuticals，在最近的收益报告中收入为 4,973,000。就地区而言， European Union 是 Advicenne SA 的主要市场，收入为 4,708,000。

Q: Advicenne SA 是否盈利？

不，根据最新的财务报表，Advicenne SA 的净损失为 $-6

Q: Advicenne SA 有负债吗？

是的，Advicenne SA 的负债为 28

Q: Advicenne SA 的流通股有多少？

Advicenne SA 的总流通股为 12.29

主页

股票

ADVVF

ADVVF 财务

Advicenne SA

0%

$0

收盘价：Jan 16, 16:00:00 GMT-5

0%

$0

盘后：Jan 16, 20:00:00 GMT-5

概述预测收益股息财务数据

收入

资产负债表

现金流量

年度

季度性

ADVVF 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
营收	2	2	2	2	2	2
营收同比增长 (YoY)	-33%	0%	0%	0%	0%	100%
营收成本	1	6	6	8	10	12
毛利润	1	-3	-3	-5	-8	-10
销售、一般及管理费用	1	5	5	1	2	2
研发	2	--	2	2	3	2
营业费用	5	7	4	4	4	3
其他非经营性收入 (费用)	0	--	0	0	0	0
税前利润	-4	-6	-7	-11	-12	-14
所得税费用	0	0	0	0	0	0
净利润	-4	-6	-7	-11	-12	-14
净利润增长	-50%	-14%	-36%	-8%	-14%	0%
稀释后流通股数	12.29	12.29	12.29	10.12	9.44	8.59
股份同比变动 (YoY)	0%	0%	21%	7%	10%	5%
每股收益 (摊薄)	-0.4	-0.52	-0.61	-1.13	-1.31	-1.72
每股收益增长率	-43%	-14%	-46%	-14%	-24%	-1%
自由现金流	--	--	-7	-9	-12	-12
每股自由现金流	--	--	--	--	--	--
毛利率	50%	-150%	-150%	-250%	-400%	-500%
营业利润率	-200%	-550%	-400%	-500%	-600%	-700%
净利率	-200%	-300%	-350%	-550%	-600%	-700%
自由现金流利润率	--	--	-350%	-450%	-600%	-600%
EBITDA	--	-9	-8	-10	-12	-14
EBITDA 利润率	--	-450%	-400%	-500%	-600%	-700%
EBITDA 中的折旧与摊销	--	2	0	0	0	0
EBIT	-4	-11	-8	-10	-12	-14
EBIT 利润率	-200%	-550%	-400%	-500%	-600%	-700%
有效税率	0%	0%	0%	0%	0%	0%

Follow-Up Questions

Advicenne SA 的关键财务报表是什么？



ADVVF 的关键财务比率是什么？



Advicenne SA 的收入按细分市场或地理位置如何划分？



Advicenne SA 是否盈利？



Advicenne SA 有负债吗？



Advicenne SA 的流通股有多少？



关键数据

前收盘价

开盘价

当日区间

52周范围

交易量

平均成交量

每股收益（TTM）

股息收益率

市值

什么是 ADVVF？

Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Paris, Ile-De-France and currently employs 15 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.

功能特性

交易策略